Published on May 31, 2021 by Raghu Patale
Asia is home to 57% of the world’s population and accounts for around 40% of the world’s pharmaceutical market. It is one of the most challenging pharmaceutical markets due to its disorganised nature. It continues to grow due to increasing populations, market size, ageing populations, and illnesses.
The challenges related to the health technology assessment (HTA), which determines reimbursement pricing, differ from country to country in Asia and are in a nascent stage unlike in most of the developed European countries. For instance, high- and upper-middle-income countries use the HTA to guide…
South Korea’s pharmaceutical market is one of the top 10 in the world and was worth USD24.3bn in 2019. It covers approximately 97% of the population under the National Health Insurance (NHI) system and follows a “positive list system” to reimburse economically and clinically valuable drugs under the NHI formulary. The country’s health technology assessment (HTA) comprises the NHI system, the Health Insurance Review Agency (HIRA), the Drug Benefit Coverage Assessment Committee (DBCAC) and the Ministry of Health and Welfare (MoHW) that together determine reimbursement prices of new drugs. …
China’s reimbursement mechanism for innovative pharmaceutical products
China’s pharma market is second only to that of the US, but China’s environment is highly competitive in terms of pricing and reimbursement of pharmaceutical products. Recent changes to China’s reimbursement policies, including frequent updates to the National Reimbursed Drug List (NRDL) and the inclusion of 250+ innovative products in the NRDL, make it a lucrative destination for pharmaceutical companies. In this insight paper, we cover the following:
Published on May 20, 2021 by Yuxi Wang
On 10 November 2020, Shanghai Clearing House announced that Yongcheng Coal & Electricity Holding Group Co., Ltd (Yongmei Holding, or Yongmei) was unable to make the RMB1bn payment of principal and interest on its super and short-term commercial paper (SCP) on time, marking another state-owned enterprise (SOE) default. It was not the first government-affiliated entity to default in the past two years. The market was, however, stunned, as investors felt they were viciously treated this time around due to a series of government-approved transactions just prior to the actual default. Through these…
Japan’s reimbursement mechanism for innovative pharmaceutical products
Japan is one of the countries that determines reimbursement pricing of pharmaceuticals the fastest. It updates its formulary four times a year, making its pharmaceutical market quite lucrative.
The country’s healthcare landscape and reimbursement pricing policies are changing rapidly. The reimbursement framework is being changed to a value-based one through the implementation of incremental cost-effectiveness ratios (ICERs) and cost‐effectiveness assessments (CEAs). In this insight paper, we cover the following:
Published on May 11, 2021 by Zahin Mohammed
Since the concept of environmental, social and governance (ESG) factors was introduced at the Who Cares Wins conference in 2005 1, it has gained significant traction among investors, asset managers and policy makers. In less than two decades, ESG and sustainable investing has grown more than 10-fold, with total assets under management associated with the theme now exceeding USD1.65tn 2. Growth was fuelled by both client demand and an unprecedented level of product development, with the total number of sustainable funds globally reaching 4,153 3at the end of December 2020.
Published on May 7, 2021 by Mamatha Subbaiah and Venkatesh Krishnamurthy
The London Interbank Offered Rate (LIBOR) is a globally accepted key benchmark interest rate used by the major global banks to lend to each other. LIBOR played a crucial role in global markets, acting as a reference rate for financial contracts and a yardstick for measuring funding costs and investment returns for a wide array of financial products, including adjustable-rate mortgages (ARMs), credit cards, floating-rate loans and swaps.
Due to the element of judgment involved in a bank’s credit risk, coupled with the global financial crisis of 2009 and…
Published on April 8, 2021 by Avishek Suman
Executive summary A host of factors are making China’s A-share market attractive to global fund managers, while at the same time, Chinese fund managers are increasingly investing in selected overseas markets for purposes of diversification and stability. Sell-side firms, on the other hand, are looking for ways to ramp up their coverage of the China market, where broker research is still patchy. …
Published on March 26, 2021 by Arjun R D
Exponential growth in personalisation initiatives, powered by an unparalleled level of access to massive datasets, has increased customer-centricity across global corporations including financial institutions. There are thousands of professionals working across business functions to make sure customers are engaged at every stage of CLM.
For example, a banking customer could own products such as deposit instruments, loan instruments and investment products. Different types and volumes of datasets emerging from unit-level legacy platforms often present serious challenges to arriving at a single version of the truth. …
Published on May 3, 2021 by Namrata Deka
Hunt for yield drives investment in…